Back to top

Analyst Blog

Abbott Laboratories (ABT - Analyst Report) announced positive interim data from the RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study. The RADICAL study analyzed samples from more than 180 critically ill patients with suspected severe infections and compared the results of Abbott's technology (IRIDICA) to the current standard of care.

The RADICAL study demonstrated that the testing platform – IRIDICA – produced results consistent with the current standard of care in just a few hours. We note that the diagnosis of serious infections as per methods currently in use takes several days.

After reviewing the interim data, physicians on a panel said that they would have prescribed a different course of treatment in more than 50% of the cases evaluated in the study. The interim results revealed that with IRIDICA physicians would be able to rule out the source of infection more confidently and quickly.

IRIDICA may be used to quickly identify microorganisms before lab cultures can detect similar results in critically ill patients with life threatening infections. IRIDICA is designed to produce results in approximately 8 hours versus days.

The RADICAL study will come to an end in late 2014 and IRIDICA will be available as a CE-marked in vitro diagnostic device in European countries within a year.

Our Take

Abbott Labs currently carries a Zacks Rank #3 (Hold). We note that Abbott Labs continues to invest in the development of next-generation instruments and other advanced technologies in its diagnostics business.

Diagnostics business sales increased 5.1% year over year (on an operational basis) to $1.1 billion in the first quarter of 2014. Abbott is investing in the development of multiple new instrument platforms to improve its diagnostic segment. The IRIDICA platform has the potential to identify life-threatening infections much faster than current methods. The approval of this testing platform will boost the diagnostic segment of the company.

Investors looking for better-ranked stocks may consider companies like Allergan (AGN - Analyst Report), Alexion Pharmaceuticals, Inc. (ALXN - Analyst Report) and Shire (SHPG - Analyst Report). All three carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
FELCOR LODG… FCH 10.47 +3.46%
OLD DOMINIO… ODFL 63.48 +1.18%
VASCO DATA… VDSI 13.57 +0.67%
AMEDISYS IN… AMED 20.18 +0.10%
LENOVO GROU… LNVGY 27.07 +0.04%